<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>APOE-Microglial-Astrocytic Axis in Cell-Type-Specific Vulnerability - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Theory Details for theory-8</h1>

        <div class="section">
            <h2>Theory (General Information)</h2>
            <div class="info-section">
                <p><strong>ID:</strong> theory-8</p>
                <p><strong>Name:</strong> APOE-Microglial-Astrocytic Axis in Cell-Type-Specific Vulnerability</p>
                <p><strong>Type:</strong> specific</p>
                <p><strong>Theory Query:</strong> Build a theory of which cell types are most susceptible and most resilient in Alzheimer's disease and the mechanisms explaining these differences, based on the following results.</p>
                <p><strong>Description:</strong> APOE genotype (particularly APOE4 vs APOE3) creates a cascade of cell-type-specific dysfunctions that modulate neuronal vulnerability. APOE4 impairs astrocytic autophagy, mitochondrial function, and neurotrophic support capacity; alters microglial metabolic programming toward pro-inflammatory states with impaired phagocytosis; and disrupts vascular endothelial function. These glial and vascular dysfunctions converge to reduce support for neurons, impair clearance of Aβ and damaged synapses, and promote inflammatory neurotoxicity. The effect is particularly pronounced in TREM2 risk variant carriers where microglial TREM2-APOE signaling is further disrupted, exacerbating loss of vulnerable neuronal subtypes. This represents a non-cell-autonomous mechanism where genotype-driven glial dysfunction determines neuronal fate.</p>
                <p><strong>Knowledge Cutoff Year:</strong> 2029</p>
                <p><strong>Knowledge Cutoff Month:</strong> 12</p>
                <p><strong>Base Model:</strong> claude-sonnet-4-5-20250929</p>
            </div>
        </div>
        </div>

        <div class="section">
            <h2>Theory (Statement/Laws)</h2>

            <h3>Theory Statements/Laws</h3>
            <hr/>
            <h3>Statement 0: APOE4 Astrocytic Dysfunction Triad</h3>
            <p><strong>Statement:</strong> APOE4-expressing astrocytes show coordinated impairment of three critical support functions: (1) reduced autophagy with mitochondrial ultrastructural alterations, (2) diminished neurotrophic support with reduced promotion of neuronal survival and synaptogenesis, and (3) altered cytokine secretion and calcium dysregulation. These deficits reduce astrocytic clearance of Aβ and impair metabolic support of neurons.</p>
            <p><strong>Domain/Scope:</strong> Applies to APOE4-homozygous or heterozygous astrocytes in human iPSC-derived models, mouse models, and human post-mortem tissue across cortical and hippocampal regions, compared to APOE3 astrocytes.</p>
            <h4>Special Cases</h4>
            <ol>
                <li>Effects may vary by brain region due to regional heterogeneity of astrocyte subtypes</li>
                <li>Age-dependent effects where astrocytic dysfunction may accumulate over time</li>
                <li>Interactions with amyloid and tau pathology may amplify dysfunction</li>
            </ol>
            <h4>Supporting Evidence for this Law</h4>
<ol>
    <li>APOE4 astrocytes show impaired autophagic function and mitochondrial/autophagic ultrastructural alterations reducing clearance capacity; APOE3 astrocytes show relatively preserved autophagy. <a href="../results/extraction-result-26.html#e26.10" class="evidence-link">[e26.10]</a> </li>
    <li>iPSC-derived APOE4/4 astrocytes show diminished neurotrophic support, reduced promotion of neuronal survival and synaptogenesis compared with APOE3/3 astrocytes. <a href="../results/extraction-result-21.html#e21.4" class="evidence-link">[e21.4]</a> </li>
    <li>PSEN1-mutant astrocytes (modeling familial AD) show increased Aβ production, altered cytokine release (IL-6, IL-8, CCL5), calcium dysregulation, and reduced lactate secretion compared to isogenic-corrected controls. <a href="../results/extraction-result-25.html#e25.3" class="evidence-link">[e25.3]</a> <a href="../results/extraction-result-21.html#e21.5" class="evidence-link">[e21.5]</a> </li>
    <li>APOE4-astrocyte interactions with TREM2 microglial pathway are described, with APOE influencing microglial responses in APOE-TREM2 axis. <a href="../results/extraction-result-26.html#e26.10" class="evidence-link">[e26.10]</a> </li>
    <li>Astrocyte ablation in mouse models increases Aβ load, indicating astrocytes contribute to clearance; APOE4 impairment would reduce this protective function. <a href="../results/extraction-result-26.html#e26.6" class="evidence-link">[e26.6]</a> </li>
    <li>Regional/age-related astrocytic atrophy, impaired AQP4 polarization, and transcriptional downregulation reduce capacity for Aβ clearance and neuronal support in AD. <a href="../results/extraction-result-26.html#e26.6" class="evidence-link">[e26.6]</a> </li>
</ol>            <h4>Self-Evaluation of Law Novelty (produced by the generation model)</h4>
            <p><strong>Likely Classification:</strong> closely-related-to-existing</p>
        <p><strong>Explanation:</strong> The integration of multiple APOE4-astrocytic dysfunctions as a coordinated mechanism affecting neuronal vulnerability represents synthesis of existing findings with iPSC-derived human cell evidence.</p>            <p><strong>What Already Exists:</strong> APOE4 as a major AD risk factor is established; astrocytic support functions and APOE expression in astrocytes are recognized.</p>            <p><strong>What is Novel:</strong> This statement integrates three specific astrocytic dysfunctions (autophagy, neurotrophic support, cytokine/calcium) as a coordinated triad specifically in APOE4 context, with evidence from iPSC-derived human cells and mechanistic links to neuronal vulnerability.</p>
        <p><strong>References:</strong> <ul>
    <li>Mahley & Rall (2000) Apolipoprotein E: far more than a lipid transport protein [APOE functions]</li>
    <li>Lin et al. (2018) APOE4 causes widespread molecular and cellular alterations associated with Alzheimer's disease phenotypes [APOE4 iPSC models]</li>
    <li>Verkhratsky et al. (2010) Astrocytes in Alzheimer's disease [Astrocytic dysfunction in AD]</li>
</ul>
            <h4>External Evaluations of this Law</h4>
            <p><strong>Predictive Accuracy Evaluation:</strong> <span class="empty-note">Not available.</span></p>
            <p><strong>Novelty Evaluation:</strong> <span class="empty-note">Not available (available only for a randomly selected subset of 100 laws, due to cost).</span></p>
            <hr/>
            <h3>Statement 1: APOE4 Microglial Metabolic Reprogramming</h3>
            <p><strong>Statement:</strong> APOE4-expressing microglia show metabolic transcriptional shifts including altered phosphocreatine/creatine kinase isoform balance (increased CKMT2/decreased CKB), dysregulated polyamine metabolism (spermidine/spermine pathways), and increased pro-inflammatory metabolites (SAM, succinate, heme) with decreased anti-inflammatory metabolites, creating a pro-inflammatory metabolic state that impairs phagocytic function and promotes neurotoxicity.</p>
            <p><strong>Domain/Scope:</strong> Applies to APOE4-expressing microglia in iPSC-derived models and mouse models, assessed by transcriptomics and metabolic network analysis (perturb-Met), comparing isogenic APOE3 vs APOE4 microglia.</p>
            <h4>Special Cases</h4>
            <ol>
                <li>Effects demonstrated primarily in iPSC-derived microglia-like cells; in vivo microglial phenotypes may differ</li>
                <li>Interaction with amyloid and tau pathology likely modulates the metabolic reprogramming</li>
                <li>Developmental stage and maturation of iPSC-derived microglia affects phenotype</li>
            </ol>
            <h4>Supporting Evidence for this Law</h4>
<ol>
    <li>APOE4 microglia show relative up-regulation of mitochondrial creatine kinase (CKMT2) vs cytosolic creatine kinase (CKB), suggesting altered phosphocreatine handling (phosphocreatine perturb-Met p=0.0029). <a href="../results/extraction-result-24.html#e24.6" class="evidence-link">[e24.6]</a> </li>
    <li>APOE4 microglia show perturbations in spermidine/spermine synthases (SRM, SMS) and metabolites linked to inflammation (SAM, succinate, heme, methylmalonyl CoA) as identified by perturb-Met. <a href="../results/extraction-result-24.html#e24.6" class="evidence-link">[e24.6]</a> </li>
    <li>Perturb-Met identified increases in metabolites promoting inflammatory activation (SAM, heme) and altered profiles of anti-inflammatory metabolites (spermidine/spermine), linking APOE4 metabolic reprogramming to inflammatory dysfunction. <a href="../results/extraction-result-24.html#e24.6" class="evidence-link">[e24.6]</a> </li>
    <li>APOE4-driven metabolic changes align with literature-supported pro-inflammatory microglial states and altered oxidative stress responses (increased nitric oxide production noted in APOE4 microglia). <a href="../results/extraction-result-24.html#e24.6" class="evidence-link">[e24.6]</a> </li>
    <li>Lipid droplet-accumulating microglia (LDAM) in aged hippocampus show impaired phagocytosis, increased ROS, and are associated with APOE4, representing dysfunctional metabolic phenotype. <a href="../results/extraction-result-26.html#e26.4" class="evidence-link">[e26.4]</a> </li>
</ol>            <h4>Self-Evaluation of Law Novelty (produced by the generation model)</h4>
            <p><strong>Likely Classification:</strong> <span style="color: orange; font-weight: bold;">somewhat-related-to-existing</span></p>
        <p><strong>Explanation:</strong> The specific metabolic pathways identified through perturb-Met represent novel molecular detail about APOE4 microglial dysfunction, though the concept of APOE4 affecting microglial metabolism is established.</p>            <p><strong>What Already Exists:</strong> APOE4 effects on microglial function and lipid metabolism are recognized; microglial metabolic reprogramming in disease states has been described.</p>            <p><strong>What is Novel:</strong> This statement identifies specific metabolic perturbations (phosphocreatine/CK isoforms, polyamine metabolism, SAM/succinate) in APOE4 microglia using metabolic network analysis (perturb-Met), providing molecular detail beyond general 'metabolic dysfunction' and linking to pro-inflammatory state.</p>
        <p><strong>References:</strong> <ul>
    <li>Krasemann et al. (2017) The TREM2-APOE pathway drives the transcriptional phenotype of dysfunctional microglia [TREM2-APOE axis]</li>
    <li>Ulland et al. (2017) TREM2 maintains microglial metabolic fitness in Alzheimer's disease [Microglial metabolism in AD]</li>
    <li>Yin et al. (2021) perturb-Met source paper [Methodology and specific APOE4 metabolic findings]</li>
</ul>
            <h4>External Evaluations of this Law</h4>
            <p><strong>Predictive Accuracy Evaluation:</strong> <span class="empty-note">Not available.</span></p>
            <p><strong>Novelty Evaluation:</strong> <span class="empty-note">Not available (available only for a randomly selected subset of 100 laws, due to cost).</span></p>
            <hr/>
            <h3>Statement 2: TREM2-APOE Synergistic Vulnerability</h3>
            <p><strong>Statement:</strong> TREM2 AD-risk variants (R47H, R62H) synergize with APOE genotype to exacerbate neuronal loss, particularly affecting vulnerable RORB+ and GAD1+ neuronal subtypes. AlzTREM2 and AlzR47H cases show greater neuronal loss (e.g., 36.3% and 25.9% additional reductions) compared to AlzCV for specific vulnerable clusters, mediated through altered microglial activation, phagocytosis, and lipid/APOE handling.</p>
            <p><strong>Domain/Scope:</strong> Applies to human cortical neurons (particularly middle temporal gyrus vulnerable subtypes) in AD patients stratified by TREM2 genotype, assessed by imaging mass cytometry and single-cell spatial analysis.</p>
            <h4>Special Cases</h4>
            <ol>
                <li>Effect magnitude varies by neuronal subtype (some clusters more affected than others)</li>
                <li>TREM2 variant effects may differ by APOE genotype (epistatic interactions)</li>
                <li>Stage-dependence where TREM2 effects may be more prominent at specific disease stages</li>
            </ol>
            <h4>Supporting Evidence for this Law</h4>
<ol>
    <li>RORB+ FOXP2+ neurons (cluster_8) show 36.3 ± 15.8% fewer cells in AlzTREM2 vs AlzCV, with TREM2 variants exacerbating loss. <a href="../results/extraction-result-27.html#e27.0" class="evidence-link">[e27.0]</a> </li>
    <li>GAD1+ FOXP2+ inhibitory neurons (cluster_32) show 25.9 ± 20.7% fewer cells in AlzTREM2 vs CtrlCV, with TREM2 genotype effects. <a href="../results/extraction-result-27.html#e27.4" class="evidence-link">[e27.4]</a> </li>
    <li>TREM2 variants modify microglial responses, and reactive microglia show increased abundance in TREM2 risk carriers, spatially associated with vulnerable neurons. <a href="../results/extraction-result-27.html#e27.6" class="evidence-link">[e27.6]</a> </li>
    <li>Disease-associated microglia (DAM) activation is TREM2-dependent, with upregulation of phagocytic genes (clec7a, spp1, itgax, apoe, trem2). <a href="../results/extraction-result-26.html#e26.0" class="evidence-link">[e26.0]</a> </li>
    <li>APOE-TREM2 pathway interactions described where astrocytic APOE influences microglial TREM2 responses and vice versa. <a href="../results/extraction-result-26.html#e26.10" class="evidence-link">[e26.10]</a> <a href="../results/extraction-result-26.html#e26.0" class="evidence-link">[e26.0]</a> </li>
    <li>TREM2-APOE pathway drives transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases (MGnD phenotype). <a href="../results/extraction-result-26.html#e26.1" class="evidence-link">[e26.1]</a> </li>
</ol>            <h4>Self-Evaluation of Law Novelty (produced by the generation model)</h4>
            <p><strong>Likely Classification:</strong> closely-related-to-existing</p>
        <p><strong>Explanation:</strong> The quantitative cell-type-specific effects of TREM2 variants on neuronal loss patterns represent refinement with high-resolution spatial data, extending established genetic associations.</p>            <p><strong>What Already Exists:</strong> TREM2 variants as AD risk factors are well-established; TREM2-APOE pathway interactions have been described in microglial biology.</p>            <p><strong>What is Novel:</strong> This statement provides cell-type-specific quantification of TREM2 variant effects on neuronal subtype loss (36.3% and 25.9% additional reductions for specific clusters) with spatial single-cell resolution, demonstrating synergistic effects on selective vulnerability.</p>
        <p><strong>References:</strong> <ul>
    <li>Jonsson et al. (2013) Variant of TREM2 associated with the risk of Alzheimer's disease [TREM2 R47H discovery]</li>
    <li>Krasemann et al. (2017) The TREM2-APOE pathway drives the transcriptional phenotype of dysfunctional microglia [TREM2-APOE pathway]</li>
    <li>Griciuc et al. (2013) Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta [Genetic risk and microglial function]</li>
</ul>
            <h4>External Evaluations of this Law</h4>
            <p><strong>Predictive Accuracy Evaluation:</strong> <span class="empty-note">Not available.</span></p>
            <p><strong>Novelty Evaluation:</strong> <span class="empty-note">Not available (available only for a randomly selected subset of 100 laws, due to cost).</span></p>
            <hr/>
            <h3>Statement 3: APOE Cell-Type-Context Specificity</h3>
            <p><strong>Statement:</strong> APOE exhibits cell-type-specific functional contexts where its role in AD varies by cell type. APOE embeddings show high similarity in microglia, neurons (especially L4 IT and certain subtypes), CD8+ T cells, and endothelial cells, while astrocyte, endothelial, and specific neuronal subclusters are predicted as most important contexts for APOE's role in AD by graph neural network fine-tuning.</p>
            <p><strong>Domain/Scope:</strong> Applies across human brain cell types in inferior temporal gyrus assessed by single-nucleus RNA-seq with cell-type-specific network analysis and graph neural network (ALZ-PINNACLE) embeddings, spanning normal aging to severe AD.</p>
            <h4>Special Cases</h4>
            <ol>
                <li>Computational predictions require experimental validation of cell-type-specific APOE functions</li>
                <li>Regional differences may affect which cell-type contexts are most important</li>
                <li>APOE genotype (E2/E3/E4) likely creates different cell-type-context dependencies</li>
            </ol>
            <h4>Supporting Evidence for this Law</h4>
<ol>
    <li>APOE cell-type-specific embeddings show high similarity in microglia, neuronal subtypes (L4 IT, Pvalb), and CD8+ T cells according to ALZ-PINNACLE analysis. <a href="../results/extraction-result-19.html#e19.0" class="evidence-link">[e19.0]</a> <a href="../results/extraction-result-19.html#e19.1" class="evidence-link">[e19.1]</a> <a href="../results/extraction-result-19.html#e19.2" class="evidence-link">[e19.2]</a> <a href="../results/extraction-result-19.html#e19.3" class="evidence-link">[e19.3]</a> <a href="../results/extraction-result-19.html#e19.4" class="evidence-link">[e19.4]</a> </li>
    <li>Fine-tuning ALZ-PINNACLE with AD GWAS genes identified astrocyte, endothelial, and neuronal subclusters as most predictive cell-type contexts for APOE's role in AD. <a href="../results/extraction-result-19.html#e19.5" class="evidence-link">[e19.5]</a> <a href="../results/extraction-result-19.html#e19.6" class="evidence-link">[e19.6]</a> </li>
    <li>Microglia (mic5) show similar APOE embeddings to neurons and are enriched for neurogenesis genes, suggesting context-specific APOE functions. <a href="../results/extraction-result-19.html#e19.0" class="evidence-link">[e19.0]</a> </li>
    <li>Astrocyte, neuronal, and microglial subtypes appear in similar embedding neighborhoods, indicating potential interaction communities mediated by APOE. <a href="../results/extraction-result-19.html#e19.5" class="evidence-link">[e19.5]</a> </li>
    <li>Endothelial cell PICALM expression (AD-associated gene involved in Aβ transcytosis/clearance) is human-enriched and represents cell-type-specific mechanism. <a href="../results/extraction-result-139.html#e139.0" class="evidence-link">[e139.0]</a> </li>
</ol>            <h4>Self-Evaluation of Law Novelty (produced by the generation model)</h4>
            <p><strong>Likely Classification:</strong> <span style="color: orange; font-weight: bold;">somewhat-related-to-existing</span></p>
        <p><strong>Explanation:</strong> The systematic computational identification of cell-type-specific APOE contexts using modern ML approaches represents a novel methodological advance in understanding APOE pleiotropy.</p>            <p><strong>What Already Exists:</strong> APOE is expressed in multiple brain cell types (especially astrocytes and microglia) and its cell-type-specific functions are being investigated.</p>            <p><strong>What is Novel:</strong> This statement uses graph neural network embeddings to systematically identify cell-type contexts where APOE function is most relevant to AD, finding unexpected similarity between microglia, neurons, and CD8+ T cells, and predicting specific contexts (astrocyte, endothelial, neuronal subclusters) as most important.</p>
        <p><strong>References:</strong> <ul>
    <li>Huang et al. (2017) ApoE2, ApoE3, and ApoE4 differentially stimulate APP transcription and Aβ secretion [Cell-type APOE effects]</li>
    <li>Lin et al. (2018) APOE4 causes widespread molecular and cellular alterations [Multi-cell-type APOE4 effects]</li>
    <li>Lewcock et al. (2024) Multi Scale Graph Neural Network source paper [Methodology for cell-type-context analysis]</li>
</ul>
            <h4>External Evaluations of this Law</h4>
            <p><strong>Predictive Accuracy Evaluation:</strong> <span class="empty-note">Not available.</span></p>
            <p><strong>Novelty Evaluation:</strong> <span class="empty-note">Not available (available only for a randomly selected subset of 100 laws, due to cost).</span></p>
            <hr/>
        </div>
        <div class="section">
            <h2>Theory (Additional Details)</h2>
                        <h3>New Predictions (Likely outcome)</h3>
            <ol>
                <li>CRISPR correction of APOE4 to APOE3 specifically in astrocytes should improve neuronal survival in co-culture or organoid AD models even without correcting neuronal APOE genotype.</li>
                <li>Transplantation of APOE3/3 astrocytes into APOE4/4 mouse models should partially rescue neuronal loss and improve cognitive function through improved metabolic support and clearance.</li>
                <li>TREM2 risk variant correction in patient-derived microglia should reduce phagocytosis of synaptic material from vulnerable neurons and reduce neuronal loss in co-culture systems.</li>
                <li>Metabolic reprogramming of APOE4 microglia (e.g., modulating polyamine or creatine metabolism) should shift them toward less inflammatory phenotypes and improve phagocytic function.</li>
                <li>Combined APOE3 astrocyte and wild-type TREM2 microglial transplantation should show synergistic neuroprotection greater than either cell type alone in AD models.</li>
            </ol>
            <h3>New Predictions (Unknown outcome/high-entropy)</h3>
            <ol>
                <li>Whether cell-type-specific APOE targeting (e.g., astrocyte-specific APOE4 suppression while leaving microglial APOE4 intact, or vice versa) would be more or less effective than global APOE4 targeting is unknown and critical for therapeutic development.</li>
                <li>Whether the APOE4-microglial metabolic reprogramming is reversible in aged microglia or represents locked-in dysfunction requiring microglial replacement is unclear and affects feasibility of metabolic interventions.</li>
                <li>Whether CD8+ T cell APOE expression and their presence in AD brain (increased in some studies) contributes significantly to pathology or represents an epiphenomenon is unknown but could represent novel immune-AD connection.</li>
                <li>Whether endothelial APOE (from pericytes/vSMCs) contributes more to Aβ clearance through perivascular drainage than astrocytic or microglial APOE is unresolved and would prioritize cell-type-specific therapeutic targeting.</li>
                <li>Whether the cell-type-specific APOE contexts identified computationally (astrocyte, endothelial, neuronal subclusters as most predictive) translate to causal mechanisms or represent correlations is unknown and requires experimental validation.</li>
            </ol>
            <h3>Negative Experiments</h3>
            <ol>
                <li>Finding that APOE4 to APOE3 correction specifically in astrocytes has no effect on neuronal survival or Aβ clearance would challenge astrocytic APOE dysfunction as a key mechanism.</li>
                <li>Demonstrating that TREM2 variant effects on neuronal loss persist even when microglial TREM2 function is fully restored would contradict the microglial-mediated TREM2 vulnerability mechanism.</li>
                <li>Showing that APOE4 microglia metabolic profiles (phosphocreatine/CK isoforms, polyamines) can be normalized without any change in inflammatory state or phagocytic function would refute the metabolic reprogramming hypothesis.</li>
                <li>Finding that cell-type-specific APOE expression patterns do not correlate with cell-type-specific vulnerability patterns would challenge the cell-type-context specificity model.</li>
                <li>Demonstrating that combined APOE3 astrocyte and wild-type TREM2 microglial interventions show no greater effect than single interventions would contradict synergistic mechanisms.</li>
            </ol>
            <h3>Unaccounted for Evidence</h3>
<ol>
    <li>The relative quantitative contributions of astrocytic vs microglial vs vascular APOE to neuronal vulnerability are not precisely determined. <a href="../results/extraction-result-26.html#e26.10" class="evidence-link">[e26.10]</a> <a href="../results/extraction-result-24.html#e24.6" class="evidence-link">[e24.6]</a> <a href="../results/extraction-result-19.html#e19.5" class="evidence-link">[e19.5]</a> <a href="../results/extraction-result-19.html#e19.6" class="evidence-link">[e19.6]</a> </li>
    <li>Temporal dynamics of how APOE4-driven glial dysfunction evolves across lifespan and disease stages are not fully characterized. <a href="../results/extraction-result-26.html#e26.10" class="evidence-link">[e26.10]</a> <a href="../results/extraction-result-21.html#e21.4" class="evidence-link">[e21.4]</a> <a href="../results/extraction-result-24.html#e24.6" class="evidence-link">[e24.6]</a> </li>
    <li>Sex-specific differences in APOE effects (APOE4 risk is greater in women) are mentioned but mechanistically not integrated into cell-type-specific framework. <a href="../results/extraction-result-26.html#e26.8" class="evidence-link">[e26.8]</a> </li>
    <li>Interactions between APOE genotype and other AD risk genes (beyond TREM2) in determining cell-type-specific vulnerability are not explored. <a href="../results/extraction-result-27.html#e27.0" class="evidence-link">[e27.0]</a> <a href="../results/extraction-result-27.html#e27.6" class="evidence-link">[e27.6]</a> </li>
</ol>        </div>        <div style="height: 30px;"></div>
    </div>
</body>
</html>